Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04442698Completed

Tailored Bilio-Pancreatic Limb and HbA1c 10 Years Post Mini-Gastric Bypass

Role: lead

NCT04442139Completed

Patient Reported Outcomes of a "Tailored" Bilio-Pancreatic Limb Length on Daily Food Choices in Mini-Gastric Bypass

Role: lead

NCT04440306Completed

"Tailored" Bilio-Pancreatic Limb Length and Weight Loss After Mini-Gastric Bypass

Role: lead

All 3 trials loaded